Optimer Pharmaceuticals' (OPTR) stock is jumping this morning after the company won ... that it signed its sales pact with Cubist before even getting approval. (See Minyanville: Optimer Readies Launch Before Drug Is Approved).
Former CEO of Optimer Pharmaceuticals, Inc. ( OPTR), Pedro Lichtinger ... and Chief Accounting Officer David Day …
We expect that OPTR will not be able to overcome the short and long-term risks to Dificid sales estimates, and that investors should either wait for a better entry point or avoid the stock entirely. Dificid discount having insufficient impact …
A stock is considered to be oversold if the RSI reading falls below 30. In trading on Wednesday, shares of Optimer Pharmaceuticals Inc (NASD: OPTR) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands …
Optimer Pharmaceuticals (Nasdaq:OPTR) hit a new 52-week high Wednesday as it is currently trading at $14, above its previous 52-week high of $13.99 with 275,132 shares traded as of 10:58 a.m. ET. Average volume has been 624,100 …
In an amended S-1 filing with the SEC, Optimer Pharmaceuticals (Nasdaq: OPTR) announced the pricing of its initial public offering of Common Stock between $12-$14 per share. The shares will begin trading today on the NASDAQ Global …
Shares of Optimer Pharmaceuticals (OPTR), for example, have begun to retreat toward levels at which buyers have historically entered the market. The stock is back in bull market territory – trading above its 200-day moving average – …
With these “truths” under our belt, let’s take a glance at the latest action encompassing Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR). In preparation for this quarter, a total of 11 of the hedge funds we track held long positions in this …
Let's discuss the ideal qualities of a perfect stock, then decide if Optimer Pharmaceuticals (UNKNOWN:OPTR.DL) fits the bill. The quest for perfection Stocks that look great based on one factor may prove horrible elsewhere, making due …
Optimer Pharmaceutical (NASDAQ: OPTR) is a biopharmaceutical company that focuses on anti-infective products, including ones that treat gastrointestinal infections and related diseases. The stock dipped last month, and looks to …